search
Wegovy
Trends
- 1One in six children on GLP-1 drugs develop deficiencies●Study: One in six children on GLP-1 drugs developed nutritional deficiencies
A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.
- 2Weight-loss jab maker sponsors Vogue World, drawing criticism●‘It’s problematic’: concern as weight-loss jab maker sponsors Vogue World event
Critics are raising concerns after Novo Nordisk, the maker of the weight-loss injection Wegovy, sponsored Vogue World, a high-profile fashion event tied to Vogue magazine. Commentators have called the partnership 'problematic', arguing that a pharmaceutical weight-loss company backing a leading fashion publication risks glamorising slimming drugs and reinforcing pressure around body image at a time when such jabs are already controversial.
- 3GLP-1 drugs, mental health and exercise in menopause examined▼GLP-1's and mental health; exercise and menopause
Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.